Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adicet Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACET
Nasdaq
8731
https://www.adicetbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adicet Bio Inc
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- Apr 22nd, 2024 8:30 pm
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
- Apr 8th, 2024 11:00 am
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Mar 28th, 2024 9:19 pm
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
- Mar 21st, 2024 10:30 am
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
- Mar 19th, 2024 8:10 pm
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Mar 11th, 2024 11:00 am
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 5th, 2024 9:01 pm
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
- Jan 25th, 2024 9:01 pm
Adicet Bio, Inc. Announces Pricing of Public Offering
- Jan 23rd, 2024 4:43 am
Adicet Bio, Inc. Announces Proposed Public Offering
- Jan 22nd, 2024 9:28 pm
Great week for Adicet Bio, Inc. (NASDAQ:ACET) institutional investors after losing 71% over the previous year
- Jan 7th, 2024 12:43 pm
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
- Jan 4th, 2024 12:00 pm
Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook
- Jan 3rd, 2024 9:01 pm
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
- Dec 10th, 2023 5:00 pm
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 8th, 2023 9:10 pm
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
- Nov 7th, 2023 12:00 pm
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
- Nov 2nd, 2023 1:00 pm
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
- Oct 4th, 2023 4:00 pm
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Sep 29th, 2023 9:24 pm
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- Sep 27th, 2023 1:00 pm
Scroll